13:11 JST, December 22, 2023
New York, Dec. 21 (Jiji Press)—American Honda Motor Co. said Thursday it will recall around 2.6 million vehicles in the United States to replace defective fuel pumps made by Japanese automotive parts maker Denso Corp.
The engine of affected vehicles could stall during driving, possibly leading to a crash, said the U.S. unit of Japan’s Honda Motor Co.
American Honda said that no crashes or injuries related to the pumps have been reported so far.
Among those subject to the recall are Accord, Civic, CR-V and Acura vehicles released between 2018 and 2020.
According to the Japanese group, it has been conducting recalls since 2020 in response to similar fuel pump problems. The total number of vehicles subject to the recalls has reached 4.5 million worldwide, including those affected by the latest action.
A Honda official said that the number is expected to rise further.
This month, Honda notified Japan’s transport ministry that it will recall around 1.13 million vehicles, including the N-Box, in the country over Denso fuel pumps.
Toyota Motor Corp. and other automakers have also taken similar steps over the pumps.
Top Articles in Business
-
Nippon Life Insurance’s U.S. Arm Sues OpenAI Over Legal Assistance Provided by ChatGPT
-
Japan, U.S. Name 3 Inaugural Investment Projects; Reached Agreement After Considerable Difficulty
-
Japan’s Major Real Estate Firms Expanding Overseas Businesses to Secure Future Growth, Focusing on Europe, U.S., Asia
-
JR Tokai Breaks Ground on Yamanashi Maglev Station; Will Be Part of Linear Chuo Shinkansen Line from Tokyo to Nagoya
-
Transport Companies See Opportunity in Narita Expansion; Airlines, Railways Prepare to Meet Expected Growth in Demand
JN ACCESS RANKING
-
Producer Behind Pop Group XG Arrested for Cocaine Possession
-
Japan PM Takaichi’s Cabinet Resigns en Masse
-
Man Infected with Measles Reportedly Dined at Restaurant in Tokyo Station
-
Japan Figure Skating Legend Yuzuru Hanyu Is Proud Disaster Survivor and Gold Medalist, Vows to Continue Support Efforts
-
iPS Treatments Pass Key Milestone, but Broader Applications Far from Guaranteed

